Results 21 to 30 of about 37,055 (199)

Europe's contribution to the evaluation of the use of systemic antimicrobials in the treatment of periodontitis

Periodontology 2000, EarlyView., 2023
Abstract This narrative review celebrates Europe's contribution to the current knowledge on systemically administered antimicrobials in periodontal treatment. Periodontitis is the most frequent chronic noncommunicable human disease. It is caused by dysbiotic bacterial biofilms and is commonly treated with subgingival instrumentation.
David Herrera, Arie Jan van Winkelhoff, Paula Matesanz, Katalina Lauwens, Wim Teughels   +4 more
wiley   +1 more source

Supra and subgingival application of antiseptics or antibiotics during periodontal therapy

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases (gingivitis and periodontitis) are characterized by inflammatory processes which arise as a result of disruption of the balance in the oral ecosystem. According to the current S3 level clinical practice guidelines, therapy of patients with periodontitis involves a stepwise approach that includes the control of the patient ...
Elena Figuero, Jorge Serrano, Nicole Birgit Arweiler, Thorsten Mathias Auschill, Ali Gürkan, Gülnur Emingil   +5 more
wiley   +1 more source

Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial [PDF]

, 2010
Background Acute exacerbations contribute to the morbidity and mortality associated with chronic obstructive pulmonary disease (COPD). This proof-of-concept study evaluates whether intermittent pulsed moxifloxacin treatment could reduce the frequency of ...
Jones, PW, Badenhorst J., Sethi S., Cukier A., Miravitlles, M, Sethi, S, Clancy L., Marlize Schmitt Theron, Bitter-Suermann S., Miravitlles Marc, Bettendorf A., Nadar R., Sanjay Sethi, Queguiner A., Rubinstein, E, Potena A., Naude G., PULSE Study group, Abenhaim N., Schroder-Babo W., Di Bartolo C., null null, Theron, MS, Kroemer B., Ferreyra R., del Campo F., de Oliveira J. A., Wedzicha J. A., Jones P. W., Killian J., Watz H., Millar A., Toubis M., Jadwiga A Wedzicha, Molitor S., Anzueto A., Gebhardt R., Groth G., Sanchez R. P., Peraza R. B., Sharafkhaneh A., Bassaris H., Smith C., Wilson Robert, Merida F. C., Fritscher C., Joubert J., Sethi Sanjay, Llamas F. S., Parada M., Alvarez-Sala L., Rubinstein Ethan, Raz P., Cote C., Vlastos F., Legnani D., Richter K., Menendez R., Barnes N. C., Viljoen J., Hasan S., Lalanne G., Wilson, R, Rubinstein E., Rastogi P., Elliott M., Bolio F. T., Fernandez P., Gaines S., Colberg K., Schaberg T., Harari S., Triot P., Monso E., Nieuwoudt G., Westerhausen U., Paul W Jones, Mans W., O'Connell F., Prins M., Dichmann R., Miravitlles M., Taminau D., Raz M., Ignacio J. M., Plautz M., Jones Paul W, Theron M. S., Zeltser D., Habib M., Kawley F., Jardim J. B., Linnhoff A., Weiler Z., Cutillas J. R., Wedzicha Jadwiga A, Robert Wilson, Barros M., Stockley R., Ethan Rubinstein, Wedzicha, JA, Wilson R., Mahutte C. K., Bugnas B., Littner M., Marc Miravitlles, Luna C., Theron Marlize, Hosp H. A., Pozzi E., Groth J., Rubinstein, Ethan, Wilson, Robert, Theron, Marlize S, Jones, Paul W, Sethi, Sanjay, Miravitlles, Marc, the PULSE Study group, Wedzicha, Jadwiga A   +118 more
core   +1 more source

Time to reconsider moxifloxacin anti-anaerobic activity?

, 2022
Large data on moxifloxacin activity on anaerobes are old. Moxifloxacin is often used for empiric therapy therefore the knowledge of current epidemiologic data is fundamental.
Richard Aschbacher, Luzzati, Roberto, Francesco Luzzaro, Luzzaro, Francesco, Roberto Luzzati, Di Bella, Stefano, Gianfranco Sanson, Stefano Di Bella, Luigi Principe, Sanson, Gianfranco, Pagani, Elisabetta, Elisabetta Pagani, Principe, Luigi, Aschbacher, Richard   +13 more
core   +1 more source

Fluoroquinolones’ Biological Activities against Laboratory Microbes and Cancer Cell Lines

Molecules, 2022
Development of novel derivatives to rein in and fight bacteria have never been more demanding, as microbial resistance strains are alarmingly increasing.
Ghadeer A. R. Y. Suaifan, Aya A. M. Mohammed, Bayan A. Alkhawaja   +2 more
doaj   +1 more source

Fluoroquinolone Persistence in Escherichia coli Requires DNA Repair despite Differing between Starving Populations

Microorganisms, 2022
When faced with nutritional deprivation, bacteria undergo a range of metabolic, regulatory, and biosynthetic changes. Those adjustments, which can be specific or independent of the missing nutrient, often alter bacterial tolerance to antibiotics.
Annabel S. Lemma, Nashaly Soto-Echevarria, Mark P. Brynildsen   +2 more
doaj   +1 more source

Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections [PDF]

, 2008
Darlene MillerAbrams Ocular Microbiology Laboratory, Bascom Palmer Eye Institute, Anne Bates Leach Eye Hospital, Miller School of Medicine-University of Miami, FL, USAAbstract: Moxifloxacin hydrochloride ophthalmic solution 0.5% (Vigamox®) is the
Darlene Miller, Miller, Darlene
core   +1 more source

Two nitazoxanide-based quadruple regimens for eradication of Helicobacter pylori infection: a single-center randomized controlled trial

Al-Azhar Assiut Medical Journal, 2022
Background and aim Eradication of Helicobacter pylori becomes an ongoing challenge worldwide because eradication rates of H. pylori are declining to less than 60% in some countries.
Amro M Hassan, Khaled Eid, Khaled A.M Eliwa, Muhammad Abdel-Gawad   +3 more
doaj   +1 more source

Emergence and spread of moxifloxacin-resistant Clostridium difficile ribotype 231 in Sweden between 2006 and 2015

New Microbes and New Infections, 2016
An aggregation of moxifloxacin-resistant Clostridium difficile ribotype 231 (RT231) isolates was first identified in the county of Stockholm in 2008, and by the end of 2015 isolates of RT231 had spread to 13 of 21 Swedish counties.
H. Harvala, E. Alm, T. Åkerlund, K. Rizzardi   +3 more
doaj   +1 more source

Clinically Compatible Fluorescence Microscopy Based on Moxifloxacin Antibiotic

, 2021
High-resolution fluorescence tissue imaging with the application of moxifloxacin as a cell-labelling agent is described. Moxifloxacin is an antibiotic used in the clinic to both treat and prevent bacterial infections, and it has both good pharmacokinetic
Ki Hean Kim, Kim, K.H., Lee, S., Seunghoon Lee   +3 more
core   +1 more source